Perfromance Wealth Partners LLC Increases Holdings in Eli Lilly and Company $LLY

Perfromance Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 14.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 4,302 shares of the company’s stock after acquiring an additional 538 shares during the quarter. Perfromance Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $4,624,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. 10Elms LLP raised its position in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares in the last quarter. M.E. Allison & CO. Inc. raised its position in shares of Eli Lilly and Company by 0.7% during the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock valued at $1,587,000 after buying an additional 10 shares in the last quarter. Bridgewater Advisors Inc. raised its position in shares of Eli Lilly and Company by 0.3% during the 3rd quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock valued at $3,018,000 after buying an additional 11 shares in the last quarter. Manske Wealth Management raised its position in shares of Eli Lilly and Company by 2.5% during the 3rd quarter. Manske Wealth Management now owns 448 shares of the company’s stock valued at $342,000 after buying an additional 11 shares in the last quarter. Finally, Verus Wealth Management LLC raised its position in shares of Eli Lilly and Company by 3.3% during the 4th quarter. Verus Wealth Management LLC now owns 343 shares of the company’s stock valued at $369,000 after buying an additional 11 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $939.79 on Friday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The firm has a market capitalization of $887.93 billion, a P/E ratio of 40.95, a price-to-earnings-growth ratio of 1.11 and a beta of 0.51. The company’s 50-day moving average is $984.00 and its 200 day moving average is $974.27.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the prior year, the company posted $5.32 EPS. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on LLY shares. Jefferies Financial Group set a $1,300.00 target price on shares of Eli Lilly and Company and gave the company a “buy” rating in a research report on Friday, March 13th. Daiwa Securities Group upped their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Bank of America increased their price objective on shares of Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. HSBC lowered shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their price objective for the stock from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Finally, Guggenheim reduced their price objective on shares of Eli Lilly and Company from $1,168.00 to $1,163.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,224.59.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo commercial launch and broad distribution—Lilly has officially launched oral GLP‑1 pill Foundayo and is rapidly expanding access through pharmacy and telehealth partners (GoodRx, WeightWatchers, LillyDirect and traditional pharmacies), which should accelerate patient uptake and revenue diversification. LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships
• Positive Sentiment: Amazon & same‑day delivery tie‑ups broaden access—Amazon Pharmacy and kiosks will stock Foundayo and offer same‑day/next‑day delivery, lowering friction for prescriptions and increasing potential volume. This distribution boost is bullish for top‑line growth. Amazon to stock Lilly’s new weight-loss pill at US kiosks, offer same-day delivery
• Positive Sentiment: Bullish analyst action—Morgan Stanley raised its price target and kept an overweight rating, signaling continued confidence in Lilly’s growth trajectory from obesity drugs and pipeline strength. Benzinga coverage of analyst action
• Neutral Sentiment: Mixed analyst views—Rothschild & Co Redburn nudged its target slightly but maintained a neutral stance, reflecting debate over near‑term pricing and margins despite long‑term opportunity. Rothschild & Co Redburn adjusts price target on Eli Lilly
• Negative Sentiment: Competitive and pricing pressure in India—Cheap generic semaglutide copies in India have reduced Lilly’s market share there, a first sign that pricing pressure and generic erosion could weigh on international sales. Eli Lilly slips as generics flood India
• Negative Sentiment: Market‑share softness as the GLP‑1 market intensifies—Reports show Lilly’s share dipping amid aggressive competition (including Novo) and cheaper alternatives, which raises near‑term revenue uncertainty. Eli Lilly’s Market Share Dips as Weight-Loss Drug War Heats Up

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.